Skip to main content
Cantargia logo

Cantargia — Investor Relations & Filings

Ticker · CANTA ISIN · SE0023312970 LEI · 549300GKWRT7RXI4VS85 ST Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2021-08-26 Regulatory Filings
Country SE Sweden
Listing ST CANTA

About Cantargia

https://cantargia.com/en/

Cantargia is a biotechnology company that develops antibody-based therapies targeting the interleukin-1 receptor accessory protein (IL1RAP). This protein is involved in signaling pathways that can drive cancer and inflammatory diseases. The company's lead asset, nadunolimab (CAN04), is a clinical-stage antibody under investigation for the treatment of various forms of cancer, including pancreatic cancer. Cantargia also developed the CAN10 program, an antibody targeting IL1RAP for autoimmune and inflammatory conditions, which was acquired by Otsuka Pharmaceutical.

Recent filings

Filing Released Lang Actions
Cantargia rapporterar behandling av första patienten i CAPAFOUR-studien som utvärderar kombination av nadunolimab och FOLFIRINOX i bukspottkörtelcancer
Regulatory Filings Classification · 95% confidence The document is a press release ("Pressmeddelande") dated August 26, 2021, announcing that the first patient has been treated in the CAPAFOUR study evaluating nadunolimab (CAN04) in combination with FOLFIRINOX for pancreatic cancer. It details the study design (Phase Ib, patient numbers, locations) and mentions that the information is being made public according to EU market abuse regulation. This type of announcement, detailing progress in clinical trials and regulatory compliance, is characteristic of a general regulatory announcement or press release that doesn't fit the specific financial report categories (like 10-K, ER, or IR). Since it is a formal announcement of company activity, and it doesn't fit the specific definitions for M&A (TAR), Capital Change (CAP/SHA), Dividend (DIV), or Director Dealing (DIRS), the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements.
2021-08-26 Swedish
Cantargia expands CIRIFOUR trial after successful completion of recruitment in the pembrolizumab combination arm
Legal Proceedings Report Classification · 99% confidence The document is a press release announcing an update regarding a clinical trial (CIRIFOUR) for a drug candidate (nadunolimab/CAN04). It details recruitment milestones, safety profiles, and plans for expanding the trial to include a new combination therapy arm. This type of announcement, which provides operational and scientific updates outside of mandated periodic financial reports (like 10-K or IR), is characteristic of general corporate news releases concerning R&D progress. Since it is not a formal financial report, a transcript, a management change, or a specific regulatory filing like a Director's Dealing or Dividend Notice, it falls best under the general category for regulatory announcements or news releases that don't fit elsewhere. Given the context of a biotechnology company updating on clinical trial progress, it is a significant corporate announcement. It is not a formal Earnings Release (ER) as it focuses on clinical data, not revenue/profit. It is not an Investor Presentation (IP) as it is a press release format. The most appropriate general category for significant, non-financial, non-management corporate news that doesn't fit a specific R&D/Legal/Capital category is Regulatory Filings (RNS), which often serves as a catch-all for important market communications, especially those mandated under market abuse regulations (as noted at the end of the text).
2021-08-19 English
Cantargia expanderar CIRIFOUR-studien efter avslutad rekrytering till kombinationsarmen med pembrolizumab
Legal Proceedings Report Classification · 99% confidence The document is a press release ("Pressmeddelande") from Cantargia AB dated August 19, 2021. It announces an update regarding the expansion of their clinical trial, CIRIFOUR, which evaluates their drug candidate CAN04 in combination with pembrolizumab for NSCLC treatment. The text details recruitment status, preliminary safety data, and plans for the next treatment arm. It concludes with standard company information and a statement that the information is being made public under the EU Market Abuse Regulation. This type of announcement, detailing clinical trial progress and business updates via a press release, is characteristic of an Earnings Release (ER) if it were focused purely on financial results, or a Regulatory Filing (RNS) if it were a general regulatory disclosure. However, since it is a specific, time-sensitive announcement about business operations (clinical trial expansion) released via a press release format, and it is not a full financial report (10-K, IR) or a specific management/governance document, it fits best as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if the company typically uses ERs for operational updates. Given the focus on clinical trial progress rather than quarterly financial figures, RNS (Regulatory Filings/General Announcement) is the most appropriate general category for this type of corporate disclosure that isn't explicitly defined elsewhere (like DIV, MANG, or DIRS). The length (6102 chars) is substantial enough to be the primary content, not just a link announcement (RPA). I will classify it as RNS as it is a general regulatory announcement via press release.
2021-08-19 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 100% confidence The document is titled 'DELÅRSRAPPORT' (Interim Report) for the period January - June 2021. It contains detailed financial highlights (Nettoomsättning, Rörelseresultat, Resultat efter skatt), operational updates, management commentary, and a project portfolio table. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H2 2021
2021-08-19 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM REPORT' and covers the period 'January - June 2021'. It contains detailed financial statements (Net sales, Operating loss, Loss after tax, etc.) for both the second quarter and the half-year, along with management commentary, project portfolio updates, and business model descriptions. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H2 2021
2021-08-19 English
Cantargia advances development of nadunolimab in triple negative breast cancer through submission of clinical protocol for TRIFOUR study
Regulatory Filings Classification · 95% confidence The document is a press release dated July 1, 2021, announcing that Cantargia AB has submitted a clinical trial application (CTA) for its TRIFOUR study investigating nadunolimab (CAN04) in triple-negative breast cancer (TNBC). It details the study design (Phase Ib/II), collaboration with GEICAM, and expected timelines. It also mentions compliance with the EU Market Abuse Regulation and provides contact information. This type of announcement, detailing progress in clinical development, regulatory submissions, or operational updates that are not standard periodic financial reports (like 10-K or IR) or specific insider transactions, falls best under a general regulatory announcement or news release category. Since it is not a formal financial report, earnings release, or a specific legal/governance document, and it is a direct announcement of a significant operational/regulatory step, it aligns most closely with a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP) if the trial submission implied a major funding milestone, but RNS is the better fit for general operational news releases that don't fit other specific categories. Given the options, 'RNS' (Regulatory Filings - General regulatory announcements and fallback category) is the most appropriate classification for a press release detailing a clinical trial submission, as it is a material event disclosure that doesn't fit the more specific financial or governance codes.
2021-07-01 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.